We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck Lands Complete Response Letter for Zetia, Vytorin sNDAs
Gilead’s Harvoni Snaps Up Additional Indications
FDA Grants Orphan Drug Designation for Remedy’s Cirara
Amgen’s Aranesp Shines in Phase 3